Input from patients, caregivers, and patient groups into Daklinza’s PharmaCare approval process is being gathered from Wednesday July 22, 2015 to MIDNIGHT on Wednesday August 19, 2015.
If you are a BC resident and answer YES to any of the following questions, you can add your input into whether or not Daklinza should be covered by BC PharmaCare:
- Do you have hep C?
- Are you a caregiver/loved one to someone who has hep C?
- Does your patient group represent patients who have hep C AND have you registered with PharmaCare to give input? (Learn more about registering your organization).
Additional Information about Daklinza (daclatasvir)
- Asunaprevir and Daclatasvir Advance
- A blog post written about Daklinza (daclatasvir) and asunaprevir when the Canadian Agency for Drugs and Technologies in Health (CADTH) began reviewing the treatments. Asunaprevir (brand name Sunvepra) is another hep C drug also seeking Canadian approval.
- Asunaprevir/Daclatasvir National Patient Consultation Webinar by the Canadian Treatment Action Council
- A webinar that explains Daklinza (daclatasvir), as well as asunaprevir, in more detail.
- A Daklinza (daclatasvir) Information Sheet by BC’s Ministry of Health
Thank you for taking the time to voice your opinion and help advocate for a better tomorrow.
*Daklinza (daclatasvir) hasn’t received a Notice of Compliance from Health Canada yet and, therefore, still can not be bought in Canada. Also, according to Advanced Notices sent out by BC PharmaCare a couple of weeks ago, there were plans to collect patient input for Sunvepra (asunaprevir) as well. The Hepatitis C Treatment Information Project will keep you informed of any of its developments.